Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.62 |
| ▸ | MMP3 | P08254 | 6/20 | 0.62 |
| ▸ | MMP7 | P09237 | 6/20 | 0.62 |
| ▸ | MMP9 | P14780 | 6/20 | 0.62 |
| ▸ | MMP13 | P45452 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886117 | 0.90 | MMP1 (0.62) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL7151963 | 0.85 | FKBP1A (0.52) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2887777 | 0.83 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL6498571 | 0.80 | MMP1 (0.55) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2888684 | 0.79 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2882601 | 0.79 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL1380196 | 0.79 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2887864 | 0.77 | MMP1 (0.48) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL27770023 | 0.77 | MMP1 (0.52) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2888598 | 0.77 | MMP3 (0.46) | MMP1MMP3MMP7MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946227-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2015-02-03 | — | — | US | claimed |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2013-06-06 | — | — | US | claimed |
| EP-1542993-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2012-12-19 | — | — | EP | claimed |
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | claimed |
| US-7754722-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2010-07-13 | — | — | US | claimed |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | MERCK SERONO SA (CH) | 2006-10-05 | — | — | US | claimed |
| EP-1542993-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | Applied Research Systems ARS Holding N.V. (AN) | 2005-06-22 | — | — | EP | claimed |
| WO-2004031182-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-04-15 | — | — | WO | claimed |
| US-8946227-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2013-06-06 | — | — | US | disclosed |
| EP-1542993-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7754722-B2 | Piperazine derivatives and methods of use | MERCK SERONO SA (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | MERCK SERONO SA (CH) | 2006-10-05 | — | — | US | disclosed |
| EP-1542993-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | Applied Research Systems ARS Holding N.V. (AN) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004031182-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305137-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | CATSPER1, NASP, HDAC5 | MMP1 1946/4885MMP3 2049/4885MMP7 2485/4885 |
| US-20130143893-A1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | CATSPER1, NASP, HDAC5 | MMP1 1946/4885MMP3 2049/4885MMP7 2485/4885 |
| US-20060223813-A1 | Piperazine Derivatives and Methods of Use | CATSPER1, H1-5, GNRHR | MMP1 2763/4885MMP3 3308/4885MMP7 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.